Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: High Grade Cervical Dysplasia Clear all
Terminated Not applicable Interventional Results available

The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

NCT00619242
View directory record Official record
Conditions
Esophageal Cancer
Interventions
sorafenib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 5, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional

LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer

NCT00260598
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Head and Neck Squamous Cell Cancer, Pulmonary Disease, Chronic Obstructive
Interventions
LIFE Bronchoscopy
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Not applicable Interventional

An Alternative Treatment for Cervical Intraepithelial Neoplasia Using the Focal Loop Electrosurgical Excision Procedure

NCT02220192
View directory record Official record
Conditions
High-grade Cervical Intraepithelial Neoplasia
Interventions
Focal LEEP
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

NCT03239223
View directory record Official record
Conditions
HSIL, HSIL of Cervix, High-Grade Squamous Intraepithelial Lesions, High-grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus, Cervical Cancer, Cervical Intraepithelial Neoplasia, Cervical Neoplasm, Cervical Dysplasia, CIN
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Los Angeles, California • Lake Worth, Florida • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

NCT00091130
View directory record Official record
Conditions
Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Interventions
HspE7, placebo, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 5, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

NCT03267680
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
Interventions
Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery
Drug · Biological · Other + 2 more
Lead sponsor
University of Southern California
Other
Eligibility
25 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Folic Acid Clinical Trial for the Prevention of Cervical Cancer

NCT00703196
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
folic acid, placebo
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03185013
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Placebo, Electroporation (EP)
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
22
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 5, 2026, 5:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT05463796
View directory record Official record
Conditions
Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Results available

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

NCT02354534
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Interventions
Artesunate Suppositories
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 5, 2026, 5:22 PM EDT
Not listed Phase 1 Interventional

Erlotinib in Treating Patients With Barrett Esophagus

NCT00566800
View directory record Official record
Conditions
Esophageal Cancer, Precancerous Condition
Interventions
erlotinib hydrochloride, laboratory biomarker analysis, biopsy
Drug · Other · Procedure
Lead sponsor
Kansas City Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 5, 2026, 5:22 PM EDT
Terminated Phase 4 Interventional

Study of LUMA Cervical Imaging System as Adjunct to Colposcopy

NCT00358111
View directory record Official record
Conditions
Dysplasia, Cancer
Interventions
Luma Cervical Imaging System
Device
Lead sponsor
SpectraScience
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Encinitas, California • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

NCT02864147
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Dysplasia
Interventions
9-valent HPV vaccine, Imiquimod
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 5, 2026, 5:22 PM EDT
Completed No phase listed Observational

CryoSpray Ablation (TM) GI Patient Registry

NCT00747448
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Not listed
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
La Jolla, California • Baltimore, Maryland • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection

NCT01022346
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Placebo, RO5217790
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
43
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03721978
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Matched Placebo, CELLECTRA™-5PSP
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Danbury, Connecticut • Newark, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit

NCT00237562
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Large loop electrosurgical excision
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 5, 2006 · Synced Oct 5, 2026, 5:22 PM EDT
Terminated Not applicable Interventional

Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer

NCT02140021
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Cervical Squamous Intraepithelial Neoplasia, Early Invasive Cervical Adenocarcinoma, Early Invasive Cervical Squamous Cell Carcinoma, High Grade Cervical Squamous Intraepithelial Neoplasia, High Grade Vaginal Intraepithelial Neoplasia, Low Grade Vaginal Intraepithelial Neoplasia, Stage I Cervical Cancer AJCC v8, Stage I Vaginal Cancer AJCC v8, Stage I Vulvar Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA Vaginal Cancer AJCC v8, Stage IA Vulvar Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB Vaginal Cancer AJCC v8, Stage IB Vulvar Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Vaginal Cancer AJCC v8, Stage II Vulvar Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Vaginal Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Vaginal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Adenocarcinoma, Vulvar Adenocarcinoma, Vulvar High Grade Squamous Intraepithelial Lesion, Vulvar Intraepithelial Neoplasia, Vulvar Squamous Cell Carcinoma, Vulvar Squamous Intraepithelial Lesion
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 5, 2026, 5:22 PM EDT
Completed No phase listed Observational

IMproved PRactice Outcomes and Value Excellence in Colposcopy

NCT02185599
View directory record Official record
Conditions
High Grade Cervical Intraepithelial Neoplasia
Interventions
DySIS
Device
Lead sponsor
DySIS Medical Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
7,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
46
States / cities
Scottsdale, Arizona • Gainesville, Florida • Jacksonville, Florida + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Esophageal Cytology With FISH in Detecting Esophageal Cancer

NCT02100189
View directory record Official record
Conditions
Dysphagia, Dysplasia, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophagitis, Gastroesophageal Reflux Disease, High Grade Dysplasia in Barrett Esophagus, Weight Loss
Interventions
Cytology Specimen Collection Procedure, Esophagogastroduodenoscopy, Laboratory Biomarker Analysis
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Results available

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

NCT00988559
View directory record Official record
Conditions
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions
DNA vaccination, Gene gun vaccine, intramuscular vaccination, intra-lesional vaccine administration, therapeutic resection of the lesion, imiquimod
Biological · Device · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

NCT00031759
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
imiquimod, Ablative or excisional therapy
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 5, 2026, 5:22 PM EDT
Completed Phase 3 Interventional

A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women

NCT00000758
View directory record Official record
Conditions
HIV Infections, Cervix, Dysplasia
Interventions
Fluorouracil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
19
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 5, 2026, 5:22 PM EDT